HUTCHMED (NASDAQ:HCM) Shares Up 6.5%

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) traded up 6.5% during mid-day trading on Thursday . The company traded as high as $21.00 and last traded at $20.73. 49,192 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 122,652 shares. The stock had previously closed at $19.47.

Analysts Set New Price Targets

Several research firms have commented on HCM. StockNews.com raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Wednesday, March 27th. Cantor Fitzgerald reiterated an "overweight" rating on shares of HUTCHMED in a research report on Friday, January 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $29.70.

HUTCHMED Stock Up 6.9 %

The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.60 and a current ratio of 2.72. The firm has a 50-day moving average price of $17.14 and a 200 day moving average price of $16.89.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HCM. Russell Investments Group Ltd. increased its stake in shares of HUTCHMED by 70.5% during the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company's stock worth $304,000 after buying an additional 7,515 shares during the period. BNP Paribas Financial Markets increased its position in shares of HUTCHMED by 54.9% in the 1st quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company's stock valued at $721,000 after purchasing an additional 15,221 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of HUTCHMED by 65.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,933 shares of the company's stock valued at $100,000 after purchasing an additional 2,340 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of HUTCHMED by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company's stock worth $958,000 after purchasing an additional 1,388 shares during the last quarter. Finally, Hsbc Holdings PLC grew its stake in shares of HUTCHMED by 821.2% during the fourth quarter. Hsbc Holdings PLC now owns 206,544 shares of the company's stock worth $3,720,000 after purchasing an additional 184,123 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company's stock.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.